RADCOM Ltd completed its acquisition of the technology, intellectual property, and customer agreements of fellow Israeli firm Continual Ltd. RADCOM announced its acquisition of the startup developed mobility experience analytics using in February. Meanwhile, RedHill Biopharma, an Israeli bio-medical firm, was granted two new EU and U.S. patents for the oncology meds RHB-102 (BEKINDA) and Opaganib.
RedHill says Opaganib is a “first-in-class,” orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component, potentially minimizing the likelihood of viral resistance.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Founded in 2009, RedHill Biopharma) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
“Between 70-80% of patients undergoing chemotherapy or radiotherapy will experience nausea and/or vomiting. The global CINV/RINV market is growing at approximately 6% CAGR and is estimated to be worth over $10 billion by 20313,” said Guy Goldberg, RedHill’s Chief Business Officer. “Following a positive recent UK MHRA scientific advice meeting RHB-102 (BEKINDA) data was deemed supportive of potential submission for marketing approval in the UK for chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV). The Company is also considering the potential for RHB-102 in additional territories and discussions with potential commercialization partners in the UK and other territories are ongoing.”
Additionally, the U.S. Patent and Trademark Office (USPTO) has granted a new patent for opaganib in respect to combination compositions for treatment of cancer, extending protection to October 2036.
Founded in 1991, RADCOM calls itself the leading expert in 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. RADCOM Network Intelligence consists of RADCOM Network Visibility, RADCOM Service Assurance, and RADCOM Network Insights. The RADCOM Network Intelligence suite offers intelligent, container-based, on-demand solutions to deliver network analysis from the RAN to the Core for 5G assurance.
Continual is a mobility experience analytics company that uses Artificial Intelligence (AI) and Machine Learning (ML) to deliver advanced insights to help telecom operators improve their subscribers’ mobility experience.
Radcom said Continual’s mobility experience analytics will enrich the company’s RADCOM ACE portfolio for location and mobility analytics, helping operators optimize the subscribers’ journey while traveling, further enhancing RADCOM’s 5G analytics to ensure users enjoy the best customer experiences wherever they are.
